Cannabis-Induced Munchies Work Through the Brain's Orexin System by Triggering More Frequent Meals

Orally consumed cannabinoid edibles caused overeating by increasing meal frequency, not meal size. This hyperphagic effect required orexin-1 (OX1) receptor signaling. Blocking the OX1 receptor eliminated both the increased eating and the temporary burst of activity following cannabinoid consumption. Both cannabinoids and the OX1 antagonist independently reduced energy expenditure hours after administration.

Male rats received cannabinoid receptor agonist (CP55940) via gelatin-based edibles. OX1 receptor involvement was tested by co-administering the antagonist SB334867. Metabolic monitoring cages captured food intake, locomotor activity, and metabolic variables simultaneously.

The "munchies" is one of the most recognizable effects of cannabis, but the neural mechanism has been unclear. Identifying the orexin pathway as essential opens possibilities for managing unwanted appetite stimulation while preserving other therapeutic effects of cannabinoids.

For patients using medical cannabis who struggle with unwanted appetite stimulation or weight gain, this research suggests the orexin system could be a target for selectively managing these side effects without eliminating other benefits.

Male rats only. One cannabinoid agonist tested (CP55940), which is synthetic and more potent than THC. Oral gelatin edible delivery is novel but may not perfectly model human edible consumption. Short-term acute study.